bioAffinity Technologies, Inc. Warrant (BIAFW) Stock Price
BIAFWStock
$0.08
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta4.48
BIAFW Share Price Chart
Favorite Metrics
Price vs S&P 500 (4W)-45.28%
VGM Score5.89
Industry Peers — R&D — Physical Sciences(16)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BIAFWbioAffinity Technologies, Inc. Warrant | — | — | F | $0.08 |
| IQVIQVIA Holdings Inc. | D | C | A | $261.75 |
| INCYIncyte Genomics Inc | C | A | B | $124.37 |
| MEDPMedpace Holdings, Inc. Common Stock | F | B | B | $600.65 |
| CRLCharles River Laboratories International, Inc. | D | D | B | $291.50 |
| ICLRIcon Plc | C | C | B | $170.02 |
| ABSIAbsci Corporation Common Stock | F | F | A | $8.71 |
| OABIOmniAb, Inc. Common Stock | D | C | A | $4.47 |
| NRCNRC Health Common Stock | D | D | B | $21.85 |
| MXCTMaxCyte, Inc. Common Stock | C | D | C | $1.22 |
| IBACIB Acquisition Corp. Common Stock | — | D | C | $10.89 |
About bioAffinity Technologies, Inc. Warrant
bioAffinity Technologies develops noninvasive diagnostic tests for early-stage cancer, particularly lung cancer, and targeted cancer therapeutics. Its proprietary CyPath Lung test uses technology that preferentially targets cancer cells to enable early-stage lung cancer detection without invasive procedures. The company addresses a significant clinical need for improved early cancer diagnosis and treatment options.